Company news
Pliant Therapeutics, Inc. (NASDAQ:PLRX) news
Every Pliant Therapeutics, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Pliant Therapeutics Receives FDA Fast Track Designation for PLN-101095 in Combination with Pembrolizumab for the Treatment of ICI-Refract...
August 18, 2026
Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results
August 11, 2026
Pliant Therapeutics Names Flavia Borellini, Ph.D. and Robert Iannone, M.D., M.S.C.E. to Board of Directors
July 13, 2026
Pliant Therapeutics Announces Upcoming Presentation at the 2026 American Society of Clinical Oncology Annual Meeting
May 21, 2026
Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results
May 11, 2026
Pliant Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference
May 6, 2026
Pliant Therapeutics Announces First Patient Dosed in FORTIFY, the Phase 1b Indication Expansion Trial Evaluating PLN-101095 in Patients w...
April 30, 2026
Pliant Therapeutics Announces Presentation of Updated Data from the Phase 1 Trial of PLN-101095 in Patients with ICI-Refractory Solid Tum...
April 18, 2026
Pliant Therapeutics Announces Upcoming Presentation of Phase 1 Clinical Trial of PLN-101095 in Patients with Solid Tumors at the 2026 AAC...
March 18, 2026
Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2025 Financial Results
March 11, 2026
Pliant Therapeutics to Participate in the Oppenheimer Healthcare Life Science Conference
February 23, 2026
Enhanced Genomics Appoints Dr Katerina Leftheris to Its Board of Directors
January 9, 2026
Pliant Therapeutics Announces Interim Data from PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors
December 4, 2025
Pliant Therapeutics to Participate in the Piper Sandler Healthcare Conference
December 1, 2025
Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results
November 6, 2025
Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results
August 7, 2025
Pliant Therapeutics Provides Update on BEACON-IPF
June 27, 2025
Pliant Therapeutics Presents Clinical and Preclinical Data at the American Thoracic Society International Conference
May 21, 2025
Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results
May 8, 2025
Pliant Therapeutics Announces Strategic Realignment of Workforce and Operations
May 1, 2025
Pliant Therapeutics Announces Upcoming Presentations at the 2025 American Thoracic Society International Conference
April 7, 2025
Pliant Therapeutics Announces Interim Phase 1 Data for PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid ...
March 17, 2025
Pliant Therapeutics Adopts Limited Duration Stockholder Rights Agreement
March 13, 2025
Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2024 Financial Results
March 3, 2025
Pliant Therapeutics Provides Update on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis
March 3, 2025
Pliant Therapeutics Announces Next Steps Following DSMB Recommendation on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulm...
February 13, 2025
Pliant Therapeutics Provides Update on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis
February 7, 2025
Pliant Therapeutics Appoints Delphine Imbert, Ph.D. as Chief Technical Officer
January 22, 2025
Pliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
January 22, 2025
Pliant Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
January 2, 2025
Pliant Therapeutics to Participate in Upcoming Investor Events
November 21, 2024
Pliant Therapeutics Presents Data from its Bexotegrast Program at The Liver Meeting® 2024
November 18, 2024
Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
November 7, 2024
Pliant Therapeutics to Participate in the Stifel Healthcare Conference
November 6, 2024
Pliant Therapeutics INTEGRIS-PSC Phase 2a Data Evaluating Bexotegrast in Primary Sclerosing Cholangitis to be Highlighted in a Late-Break...
October 17, 2024
Pliant Therapeutics Appoints Gary Palmer, M.D. as Senior Vice President of Medical Affairs
October 1, 2024
Pliant Therapeutics Presents Data from its Bexotegrast Program at the European Respiratory Society International Congress 2024
September 10, 2024
Pliant Therapeutics Announces Four Upcoming Presentations at the European Respiratory Society International Congress 2024
August 26, 2024
Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results
August 7, 2024
Pliant Therapeutics to Participate in the Canaccord Genuity 44th Annual Growth Conference
August 6, 2024
Pliant Therapeutics Announces Positive Long-Term Data from the INTEGRIS-PSC Phase 2a Trial Demonstrating Bexotegrast was Well Tolerated a...
July 15, 2024
Pliant Therapeutics Announces Appointment of Steve Krognes to Board of Directors
June 13, 2024
Pliant Therapeutics Presents Data from its Bexotegrast Program at the European Association for the Study of the Liver (EASL) Internationa...
June 6, 2024
Pliant Therapeutics Presents Data from its Bexotegrast Program at the American Thoracic Society International Conference
May 21, 2024
Pliant Therapeutics Announces Positive Topline Data from a Phase 2a Collagen PET Imaging Clinical Trial of Bexotegrast in Patients with I...
May 14, 2024
Pliant Therapeutics Announces Upcoming Presentations at the European Association for the Study of the Liver International Liver Congress™
May 7, 2024
Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
May 6, 2024
Pliant Therapeutics Announces Upcoming Presentations at the 2024 American Thoracic Society International Conference
March 27, 2024
Pliant Therapeutics Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis
March 12, 2024
Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2023 Financial Results
February 27, 2024